Rein Therapeutics RNTX
NASDAQ RNTX
$0.81 +0.02 (+2.10%)
As of: Aug 21, 2026 · 3:14 PM EDT

Rein Therapeutics (RNTX) Total Non-Current Liabilities (2024 - 2025)

Rein Therapeutics (RNTX) posted quarterly Total Non-Current Liabilities of $7.2 million for Q4 2025, down 3.74% year-over-year from $7.5 million in Q4 2024, and down 3.67% quarter-over-quarter from $7.5 million in Q3 2025.

Rein Therapeutics (RNTX) Total Non-Current Liabilities (2024 - 2025) Analysis & Trends

Rein Therapeutics (RNTX) has reported Total Non-Current Liabilities for 2 consecutive years, with $7.2 million the latest figure, recorded in Q4 2025.

  • In Q4 2025, Total Non-Current Liabilities fell 3.74% year-over-year to $7.2 million; the TTM figure through Dec 2025 stood at $7.2 million (down 3.74% YoY), while the FY2025 annual figure was $7.2 million, down 3.74% from the prior year.
  • Total Non-Current Liabilities eased to $7.2 million in Q4 2025 per RNTX's latest filing, from $7.5 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $9.5 million in Q2 2025 and bottomed at $7.2 million in Q4 2025.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Vertex Pharmaceuticals 138.93 Bn 131.07 Bn 2.84 Bn 5.92 Bn
2 Regeneron Pharmaceuticals 85.91 Bn 77.92 Bn 3.93 Bn 7.74 Bn
3 Argenx Se 64.98 Bn 59.80 Bn 1.37 Bn 40.00 Mn
4 Moderna 58.86 Bn 53.72 Bn 52.00 Mn 3.92 Bn
5 BeOne Medicines 42.03 Bn 36.93 Bn 1.53 Bn 1.88 Bn
6 Alnylam Pharmaceuticals 31.54 Bn 28.23 Bn 992.69 Mn 4.20 Bn
7 BioNTech SE 27.88 Bn 9.49 Bn 668.28 Mn 724.15 Mn
8 Insmed 27.44 Bn 26.28 Bn 358.27 Mn 1.17 Bn
9 Royalty Pharma 27.35 Bn 26.51 Bn - 9.32 Bn
10 Rein Therapeutics 54.36 Mn 54.36 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2025 7.24 Mn
Sep 30, 2025 7.52 Mn
Jun 30, 2025 9.47 Mn
Mar 31, 2025 7.75 Mn
Dec 31, 2024 7.52 Mn
Jun 30, 2024 8.26 Mn